<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237805</url>
  </required_header>
  <id_info>
    <org_study_id>SAF001</org_study_id>
    <nct_id>NCT04237805</nct_id>
  </id_info>
  <brief_title>A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>A Phase I/II, Multi-center Clinical Study: Dose-finding Phase I Study of Foritinib Succinate in Advanced ALK-positive NSCLC Patients and Phase II Study of Foritinib Succinate in ALK or ROS1-positive NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fosun Pharmaceutical Development Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fosun Pharmaceutical Development Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study comprises two phases: phase I dose escalation (including PK run-in period and&#xD;
      treatment period) and phase II study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, single-arm, open-label dose-finding phase I/II study to determine the&#xD;
      MTD and RP2D of oral foritinib succinate monotherapy in patients with advanced ALK-positive&#xD;
      malignant solid tumor, and to evaluate the safety, tolerability, and PK characteristics of&#xD;
      SAF-189s in patients with advanced ALK-positive NSCLC. Phase II clinical study was conducted&#xD;
      to evaluate the efficacy, tumor activity, and safety of remitinib succinate in patients with&#xD;
      ALK/ROS1 positive advanced non-small cell lung cancer, and to preliminary evaluate the&#xD;
      population pharmacokinetic characteristics of remitinib succinate.&#xD;
&#xD;
      This study consisted of two phases: phase I (including PK induction and continuous&#xD;
      administration) and phase II, Phase I dose escalation : the patients with advanced&#xD;
      ALK-positive malignant solid tumor who have progressed on standard therapies; Phase I study:&#xD;
      histologically or cytologically confirmed, locally advanced ALK-positive and/or metastatic&#xD;
      stage IIIB/IV NSCLC who have progressed on standard therapy; Phase II Study Part I: Patients&#xD;
      with histologically and/or cytologically confirmed ALK or ROS1 positive locally-advanced&#xD;
      and/or metastatic stage IIIb ~IV NSCLC;Patients who had not previously received or had&#xD;
      received only one ALK/ROS1 inhibitor for disease progression or intolerance, and who had no&#xD;
      more than 3 previous treatment lines overall Phase II Study Part Ⅱ: cohort1：ROS1-positive&#xD;
      locally advanced and/or metastatic stage IIIB~IV NSCLC patients diagnosed histologically&#xD;
      and/or cytologically, with no prior systemic therapy or only one line of non-ROS1-inhibitor&#xD;
      treatment cohort 2: patients with histologically and/or cytologically confirmed ROS1-positive&#xD;
      locally advanced and/or metastatic stage IIIb ~IV NSCLC who had previously only received&#xD;
      crizotinib as a ROS1 inhibitor for disease progression or intolerance and had no more than 3&#xD;
      overall previous treatment lines；&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>24 days after the first dose in the dose escalation phase</time_frame>
    <description>Dose Limiting Toxicity incidence within 24 days after the first dose in the dose escalation phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>until 6 months' treatment of the last patients in each cohort</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TEAE</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>TEAE incidence, types, grade of toxicity according to NCI-CTCAE (version 5.0); study-related TEAE, SAE, study-related SAE, ≥ Grade 3 TEAE, ≥ Grade 3 TESAE, and TEAE leading to permanent discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR</measure>
    <time_frame>3 years</time_frame>
    <description>clinical benefit rate (CBR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>3 years</time_frame>
    <description>duration of response (DoR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>4 years</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>1 years</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS responses</measure>
    <time_frame>4 years</time_frame>
    <description>Central nervous system efficacy evaluation，（time to CNS progression，CNS TTP），（CNS objective response rate，CNS ORR）,（duration of CNS response，CNS DOR）</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <arm_group>
    <arm_group_label>SAF-189s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAF-189s</intervention_name>
    <description>20mg，40mg，80mg，120mg，160mg，210mg，once daily</description>
    <arm_group_label>SAF-189s</arm_group_label>
    <other_name>foritinib succinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Have a full understanding of this study and voluntarily sign an informed consent form&#xD;
        (ICF) 2）Phase I dose escalation : the patients with advanced ALK-positive malignant solid&#xD;
        tumor who have progressed on standard therapies; Phase I study: histologically or&#xD;
        cytologically confirmed, locally advanced ALK-positive and/or metastatic stage IIIB/IV&#xD;
        NSCLC who have progressed on standard therapy; Phase II Study Part I: Patients with&#xD;
        histologically and/or cytologically confirmed ALK or ROS1 positive locally-advanced and/or&#xD;
        metastatic stage IIIb ~IV NSCLC;Patients who had not previously received or had received&#xD;
        only one ALK/ROS1 inhibitor for disease progression or intolerance, and who had no more&#xD;
        than 3 previous treatment lines overall Phase II Study Part Ⅱ: cohort1：ROS1-positive&#xD;
        locally advanced and/or metastatic stage IIIB~IV NSCLC patients diagnosed histologically&#xD;
        and/or cytologically, with no prior systemic therapy or only one line of non-ROS1-inhibitor&#xD;
        treatment cohort 2: patients with histologically and/or cytologically confirmed&#xD;
        ROS1-positive locally advanced and/or metastatic stage IIIb ~IV NSCLC who had previously&#xD;
        only received crizotinib as a ROS1 inhibitor for disease progression or intolerance and had&#xD;
        no more than 3 overall previous treatment lines； 3) At least one measurable lesion per&#xD;
        RECIST1.1; Note: a lesion previously treated by radiotherapy is not considered as a target&#xD;
        lesion, unless confirmed progression is documented after radiotherapy.&#xD;
&#xD;
        4) ECOG performance score ≤ 2; 5) Male or female patients ≥ 18 and ≤ 75 years old in Phase&#xD;
        I ；Male or female patients ≥ 18 in Phase II 6) Life expectancy ≥ 12 weeks; 7) Patient with&#xD;
        appropriate organ function as documented by:&#xD;
&#xD;
          1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;&#xD;
&#xD;
          2. Hemoglobin ≥ 90 g/L;&#xD;
&#xD;
          3. Platelets (PLT) ≥ 100 × 109/L&#xD;
&#xD;
          4. Serum total bilirubin ≤ 1.5 × ULN (if the patient has Gilbert's syndrome, ≤ 3 × ULN&#xD;
             and direct bilirubin ≤ 1.5 × ULN);&#xD;
&#xD;
          5. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN&#xD;
             for patient with liver metastases);&#xD;
&#xD;
          6. Creatinine clearance (CrCL) ≥ 50 mL/min (calculated by Cockcroft-Gault equation)&#xD;
&#xD;
          7. Fasting blood glucose ≤ 200 mg/dL (≤ 11.1 mmol/L) 8) Toxicities from any prior&#xD;
             therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 per NCI-CTCAE&#xD;
             (Version 4.03), exception of alopecia; 9）Within 21 days prior to enrolment, women of&#xD;
             reproductive age had to confirm a negative serological pregnancy test and agree to use&#xD;
             an effective contraceptive method for all study drug use and for 28 days after the&#xD;
             last dose.For the purposes of this protocol, women of childbearing age are defined as&#xD;
             sexually mature women who: 1) have not undergone hysterectomy or bilateral&#xD;
             oophorectomy, or 2) have natural menopause that has not lasted continuously for 24&#xD;
             months (amenorrhea after cancer treatment does not exclude fertility) (i.e., have had&#xD;
             menstruation at any time during the previous consecutive 24 months);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has had prior chemotherapy, anti-cancer treatment with biological drugs, or other&#xD;
             investigational agents within 28 days or received TKI or targeted therapies within 14&#xD;
             days prior to enrollment;&#xD;
&#xD;
          2. Received radiotherapy within 21 days prior to the 1st dose or continuance of&#xD;
             toxicities due to prior radiotherapy that do not recover to Grade 0 or 1;&#xD;
&#xD;
          3. Patients who received major surgery within 3 weeks before enrollment or have not&#xD;
             adequately recovered from prior surgery;&#xD;
&#xD;
          4. Patients with central nervous system (CNS) metastases requiring&#xD;
&#xD;
               1. Clinical local intervention such as surgical excision, radiotherapy or other&#xD;
                  therapies&#xD;
&#xD;
               2. Phase I dose escalation: patients requiring systemic treatment with&#xD;
                  corticosteroids (&gt;10 mg/day prednisone or equivalent) are not eligible for dose&#xD;
                  escalation study (not applicable to patients participating Phase I cohort&#xD;
                  expansion or Phase II).&#xD;
&#xD;
          5. Diabetics without stable control and with insulin therapy (patients with fasting blood&#xD;
             glucose below 7mmol/L, who are receiving stable hypoglycemic drug regimen, and whose&#xD;
             blood glucose control is stable as evaluated by specialist doctors are allowed to be&#xD;
             enrolled); 6）Difficulty in swallowing or having an active digestive disorder or having&#xD;
             undergone major gastrointestinal surgery may significantly affect the administration&#xD;
             or absorption of SAF189s (e.g. ulcerative lesions, uncontrollable nausea, vomiting,&#xD;
             diarrhoea, malabsorption syndrome, and enteroctomies) 7）Patients who are taking the&#xD;
             following medicines:&#xD;
&#xD;
               1. Repaglinide (cytochrome [CYP]2C8) and drugs metabolized via CYP3A4 enzyme within&#xD;
                  1 week before enrollment;&#xD;
&#xD;
               2. Medicines which are known to cause QT prolongation or torsade de pointes;&#xD;
&#xD;
               3. Coumarin anticoagulants within 1 week before enrollment (low molecular weight&#xD;
                  heparin is permitted);&#xD;
&#xD;
               4. Illegal drugs;&#xD;
&#xD;
        8) Has a history of acute pancreatitis within 1 year before enrollment, or past history of&#xD;
        chronic pancreatitis; 9) Patients have positive laboratory test for anti-HCV, or are&#xD;
        diagnosed with human immunodeficiency virus (HIV) infection, or who refuse to receive HIV&#xD;
        screen test; 10) Patients have other malignant tumor history or with other malignant tumors&#xD;
        simultaneously; 11) Impairment of cardiac function or clinically significant heart disease,&#xD;
        including New York College of Cardiology (NYHA) grade ≥ 3 congestive heart failure,&#xD;
        arrhythmias, conduction abnormalities requiring treatment, cardiomyopathy, or uncontrolled&#xD;
        hypertension； 12) Corrected QT interval using Fridericia formula &gt; 450 msec for male&#xD;
        patients and &gt; 470 msec for female patients; 13) Patients have uncured interstitial lung&#xD;
        disease history or non-infectious pneumonitis prior to enrollment, except for those induced&#xD;
        by radiation therapy; 14）Any other clinically significant disease or condition (such as&#xD;
        uncontrolled diabetes, active or uncontrolled infections, etc.) that the investigator&#xD;
        believes could affect protocol adherence or affect the patient's ability to sign up for&#xD;
        ICF; 15）Spinal cord metastases with potential risk or symptoms of spinal cord compression；&#xD;
        16）The second cohort received ROS1 inhibitors other than crizotinib； 17）The patient had&#xD;
        uncontrollable amounts of pleural effusion, ascites, and pericardial effusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province People's General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinji Yang, Doctor</last_name>
    <phone>+86-020-83827812</phone>
    <email>yangjinji2003@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>he First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li, Doctor</last_name>
      <phone>13965282263</phone>
      <email>bbmcliwei@126.com</email>
    </contact>
    <investigator>
      <last_name>Wei Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100140</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, Doctor</last_name>
      <phone>13911339836</phone>
      <email>zhanglipumch@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziping Wang, Doctor</last_name>
      <phone>13301212676</phone>
      <email>wangzp2007@126.com</email>
    </contact>
    <investigator>
      <last_name>Ziping Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Liu, Doctor</last_name>
      <phone>13651392121</phone>
      <email>liuzhe1968@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Zhe Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Province People's General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinji Yang, Doctor</last_name>
      <phone>+86-020-83827812</phone>
      <email>yangjinji2003@163.com</email>
    </contact>
    <investigator>
      <last_name>Yilong Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinji Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wangjun Liao, doctor</last_name>
      <phone>13711448429</phone>
      <email>nfyyzlklwj@163.com</email>
    </contact>
    <investigator>
      <last_name>Wangjun Wangjun, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518116</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi Jin, Doctor</last_name>
      <phone>18823361670</phone>
      <email>catherine-jinshi@163.com</email>
    </contact>
    <investigator>
      <last_name>Shi Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang, Master</last_name>
      <phone>13930881628</phone>
      <email>booszam@sina.com</email>
    </contact>
    <investigator>
      <last_name>Aimin Zang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuimin Ding, Master</last_name>
      <phone>13633083069</phone>
      <email>wjwdcm@sina.com</email>
    </contact>
    <investigator>
      <last_name>Cuimin Ding, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GongYan Chen, Doctor</last_name>
      <phone>13633668886</phone>
      <email>chengongyan@163.com</email>
    </contact>
    <investigator>
      <last_name>GongYan Chen, Dcotor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Li, Doctor</last_name>
      <phone>13526502916</phone>
      <email>didilmj4505@sina.com</email>
    </contact>
    <investigator>
      <last_name>Mingjun Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Central Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanyong Yi, Doctor</last_name>
      <phone>15516991321</phone>
      <email>yisy2001@126.com</email>
    </contact>
    <investigator>
      <last_name>Shanyong Yi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiye Zhang, Master</last_name>
      <phone>13783100985</phone>
      <email>13783100985@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhiye Zhang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiangtao Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Chen, Doctor</last_name>
      <phone>18874052067</phone>
      <email>chenyuan008@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuan Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Dong, Doctor</last_name>
      <phone>13986252286</phone>
      <email>hustwuhan@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiaorong Dong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanping Hu, Master</last_name>
      <phone>13971385149</phone>
      <email>h-y-p@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanping Hu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, Doctor</last_name>
      <phone>+86-0731-89762320</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <investigator>
      <last_name>Nong Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Yongzhou</name>
      <address>
        <city>Yongzhou</city>
        <state>Hunan</state>
        <zip>425006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengfei Luo, Master</last_name>
      <phone>‭18608462505‬</phone>
      <email>76756518@qq.com</email>
    </contact>
    <investigator>
      <last_name>Pengfei Luo, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongqian Shu, Doctor</last_name>
      <phone>13951017570</phone>
      <email>shuyongqian@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yongqian Shu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Xuzhou Mining Group</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoqing Wang, Master</last_name>
      <phone>13952234612</phone>
      <email>13952234612@163.com</email>
    </contact>
    <investigator>
      <last_name>Baoqing Wang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anwen Liu, Doctor</last_name>
      <phone>13767120022</phone>
      <email>awliu666@163.com</email>
    </contact>
    <investigator>
      <last_name>Anwen Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuwei Cui, Doctor</last_name>
      <phone>15843073215</phone>
      <email>jdyycjw@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiuwei Cui, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng, Bachelor</last_name>
      <phone>0431-85871902</phone>
      <email>Jl.cheng@163.com</email>
    </contact>
    <investigator>
      <last_name>Ying Cheng, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yanbian University Affiliated Hospital</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xionghu Shen, Doctor</last_name>
      <phone>15526770368</phone>
      <email>xim918@126.com</email>
    </contact>
    <investigator>
      <last_name>Xionghu Shen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, Doctor</last_name>
      <phone>13898865122</phone>
      <email>cmu_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Yunpeng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuping Sun, Doctor</last_name>
      <phone>13370582181</phone>
      <email>sunypclinicaltrial@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuping Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No. 960 Hospital of the Joint Service Support Force of Chinese People's Liberation Army</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baocheng Wang, Doctor</last_name>
      <phone>13605310886</phone>
      <email>baochengwang960@sina.com</email>
    </contact>
    <investigator>
      <last_name>Baocheng Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Qianfoshan Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang, Doctor</last_name>
      <phone>15806655997</phone>
      <email>ggjun2005@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JianHua Shi, Master</last_name>
      <phone>15963998868</phone>
      <email>shijianhualy@126.com</email>
    </contact>
    <investigator>
      <last_name>JianHua Shi, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital,Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyan Jiang, Doctor</last_name>
      <phone>13916146759</phone>
      <email>jiang_liyan2000@126.com</email>
    </contact>
    <investigator>
      <last_name>Liyan Jiang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jieyang Peoples Hospital</name>
      <address>
        <city>Jieyang</city>
        <state>Shanxi</state>
        <zip>522000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofen Wang, Bachelor</last_name>
      <phone>13542211822</phone>
      <email>82395946@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaofen Wang, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Wang, Doctor</last_name>
      <phone>18980602252</phone>
      <email>WangKeWK2019@126.com</email>
    </contact>
    <investigator>
      <last_name>Ke Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second peoples hospital of Neijiang</name>
      <address>
        <city>Neijiang</city>
        <state>Sichuan</state>
        <zip>641100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ou Jiang, Doctor</last_name>
      <phone>13990570757</phone>
      <email>jiangou816@163.com</email>
    </contact>
    <investigator>
      <last_name>Ou Jiang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <phone>13821377353</phone>
      <email>zhongdsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changli Wang, Doctor</last_name>
      <phone>13821086868</phone>
      <email>wangchangli309@163.com</email>
    </contact>
    <investigator>
      <last_name>Changli Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Peoples Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaqing Wang, Doctor</last_name>
      <phone>18622221223</phone>
      <email>huaqingw@163.com</email>
    </contact>
    <investigator>
      <last_name>Huaqing Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Zhou, Doctor</last_name>
      <phone>+86-0571-87236877</phone>
      <email>drzjy@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianying Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqin Lu, Bachelor</last_name>
      <phone>13858039628</phone>
      <email>llq99@163.com</email>
    </contact>
    <investigator>
      <last_name>Liqin Lu, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SIR RUN RUN SHAW HOSPITAL Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, Doctor</last_name>
      <phone>13605716662</phone>
      <email>shonco@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Hongming Pan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Fan, Doctor</last_name>
      <phone>13858182310</phone>
      <email>fanyun@zjcc.com</email>
    </contact>
    <investigator>
      <last_name>Yun Fan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shulan (Hangzhou) Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhengjiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao, Doctor</last_name>
      <phone>13588119268</phone>
      <email>jade1972@126.com</email>
    </contact>
    <investigator>
      <last_name>Qiong Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK-rearranged</keyword>
  <keyword>ALK-positive</keyword>
  <keyword>ROS1-rearranged</keyword>
  <keyword>ROS1-positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

